Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma.
Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence.
“This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].”
Singhal and his colleagues from the Abramson Cancer Center at the University of Pennsylvania in Philadelphia detailed their recent study of the technique in The Annals of Thoracic Surgery.
Abramson is currently the only cancer center using the TumorGlow technology, devised by Singhal, to improve the detection of macroscopic residual disease during surgery for mesothelioma.
A More Complete Resection
The recent study involved 20 surgical patients at Abramson with pleural mesothelioma between January 2016 and April 2017.
All procedures were done by either Singhal or thoracic surgeon Dr. John Kucharczuk.
“It always disappointed me that you’d do the complete surgery and the cancer was still coming back,” he said. “In the past, we were leaving behind cancer cells we couldn’t see. This way, we can get it all.”
Although the goal of the pleurectomy and decortication (P/…
You’re reading Toxins In The Home: What You Don’t Know Might Kill You, originally posted on Pick the Brain | Motivation and Self Improvement. If you’re enjoying this, please visit our site for more inspirational articles.
Poisoning is the number one cause of injury-related deaths in the United States, and 91% of incidents occur in our very own homes. Unintentional poisoning can occur in a number of ways, potentially harming our health as well as our loved ones. In an effort to reduce the number of households affected, it’s important to understand where common toxic products might be lurking and how to create a …
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer.
Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies.
In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients.
The trial success has led the manufacturer t…
It is common for cancer patients to experience fatigue during and after cancer treatment.
Fatigue usually lessens as patients recover, but some patients experience long-term fatigue that gets in the way of the things they want to do.
Mesothelioma survivors are among the many cancer patients who cope with fatigue once treatment ends.
New research conducted by scientists at the University of Alabama at Birmingham and Harvard Medical School shows cancer-related fatigue can be relieved by a placebo pill. This relief even occurs when patients are aware they are taking a placebo, known as open-label placebo.
A placebo is anythin…
In this study, a series of deletion or point mutants of cPDPN were utilized for investigating the binding epitopes of PMab-52 using flow cytometry and Western blotting. The findings of this study revealed that the critical epitopes of platelet aggregation-stimulating domain 4 (PLAG4) of cPDPN are responsible for the binding of PMab-52 to cPDPN.
PMID: 29394131 [PubMed – as supplied by publisher]
ConclusionsPostoperative BNP measurement after CRS + HIPEC may guide postoperative fluid resuscitation and facilitate identification of patients at risk for major and/or cardiopulmonary complications.
In this study, we investigated podoplanin expression in 40 feline squamous cell carcinomas (14 cases of mouth floor, 13 of skin, 9 of ear, and 4 of tongue) by immunohistochemical analysis using an anti-cat podoplanin mAb PMab-52, which we recently developed by cell-based immunization and screening (CBIS) method. Of the total 40 cases, 38 (95%) showed positive staining for PMab-52. In particular, 12 cases (30%) showed a strong membrane-staining pattern of squamous cell carcinoma cells. PMab-52 can be useful for antibody therapy against feline podoplanin-expressing squamous cell carcinomas.
PMID: 29090969 [PubMed – as supplied by publisher]
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results.
The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year.
Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street.
Conclusions • Physicians should have no hesitation prescribing natural progesterone. The evidence is clear that progesterone does not cause breast cancer. Indeed, progesterone is protective and preventative of breast cancer.
PMID: 29055286 [PubMed – as supplied by publisher]
BACKGROUND: Emergency diagnosis of cancer is common and aetiologically complex. The proportion of emergency presenters who have consulted previously with relevant symptoms is uncertain.
AIM: To examine how many patients with cancer, who were diagnosed as emergencies, have had previous primary care consultations with relevant symptoms; and among those, to examine how many had multiple consultations.
DESIGN AND SETTING: Secondary analysis of patient survey data from the 2010 English Cancer Patient Experience Survey (CPES), previously linked to population-based data on diagnostic route.
This study provides evidence that some patients [with mesothelioma] can have long-term disease control with this drug, which we haven’t seen before,” Alley said in a press release. “This drug appears to be well tolerated.”
Real Need for Second-Line Therapy
Standard first-line therapy for mesothelioma includes a combination of chemotherapy, radiation and surgery, but it remains relatively ineffective as a long-term solution.
Alley believes pembrolizumab, classified as a checkpoint inhibitor drug, can provide a needed advancement in treatment.
Checkpoint inhibitors allow the immune system to fight off…